Prostate Cancer

Four of 5 patients with prostate cancer and ctDNA positivity had disease progression following treatment with darolutamide plus androgen deprivation therapy in a phase 2 trial.

Six months of intensified androgen deprivation therapy plus next-generation anti-androgens may be an attractive option for those with prostate cancer and rising prostate specific antigen levels following prostatectomy.

The overall incidence of bone fractures with prior EBRT to the bone in patients with metastatic castration-resistant prostate cancer remains low.

Additional education on tumor testing and PARP inhibitor therapy is warranted for patients with metastatic castration-resistant prostate cancer, according to Neal Shore, MD, FACS.

Findings support cabozantinib plus atezolizumab as a potential new treatment option for those with metastatic castration-resistant prostate cancer that has progressed on a novel hormonal therapy.

The FDA previously granted approval to frontline olaparib plus abiraterone/prednisone in May 2023 for BRCA1/2–, DDR–altered metastatic castration-resistant prostate cancer.

Darolutamide correlates with a marginally longer length of stay per hospitalization compared with placebo among those with metastatic hormone-sensitive prostate cancer.

While the overall survival between patients receiving cabazitaxel and those receiving Lu-PSMA-617 had negligible difference, the results of the phase 2 TheraP trial supports the use of Lu-PSMA-617 as an alternative treatment for prostate cancer.

Compared with surgery and radiation, focal therapy improves quality of life as well as decreases financial toxicity for patients with prostate cancer.

Including minority populations in clinical trials can be most easily done through outreach and partnerships with other health centers, according to Adam B. Murphy, MD, MBA, MSCI.

Artificial intelligence models may be “seamlessly incorporated” into clinical workflow in the management of prostate cancer, says Eric Li, MD.

Realigning value-based models to increase reimbursement for hypofractionated radiotherapy in prostate cancer may minimize barriers to access among underserved communities.

Robust genetic testing guidelines in the prostate cancer space must be supported by strong clinical research before they can be properly implemented, says William J. Catalona, MD.

Radiographic progression-free survival outcomes with olaparib plus abiraterone acetate and prednisone appear to be consistent with prior analyses of the phase 3 PROpel trial.

Docetaxel plus standard of care may be beneficial among patients with prostate cancer and low prostate-specific antigen levels who do not have any highly effective treatment options, says Anthony D’ Amico, MD, PhD.

Financial constraints and a lack of education among some patients and providers must be addressed to improve the real-world use of certain prostate cancer therapies, says Neeraj Agarwal, MD.

Results from a phase 1 of study of 177Lu-PSMA-617 in combination with pembrolizumab show significant anti-tumor activity with low toxicity in patients with metastatic castration-resistant prostate cancer.

With the announcement that the supply of 177Lu vipivotidete traxetanis now unconstrained, the targeted radioligand will be available in over 200 centers for patients with prostate cancer. 

Novel anti-PSMA monoclonal antibody rosopatamab is capable of carrying a bigger payload of radiation particles, which may potentially reduce doses for patients with prostate cancer, says Neeraj Agarwal, MD.

Investigators will assess the safety and preliminary anti-tumor activity of ONCT-534 in metastatic castration-resistant prostate cancer in the phase 1/2 study ONCT-534-101.

The Canadian approval of relugolix for advanced prostate cancer is based on findings from the phase 3 HERO study.

Findings from recent studies support the use of artificial intelligence-based tools in the context of radiation therapy for patients with localized prostate cancer, according to Neeraj Agarwal, MD.

Data from a phase 2 trial suggests that earlier use of abiraterone acetate/prednisone plus cabazitaxel may elicit clinical benefit in patients with metastatic castration-resistant prostate cancer.

Median radiographic progression-free survival appears to be higher in patients with metastatic castration-resistant prostate cancer treated with 177Lu-PSMA-617 than those receiving androgen receptor pathway inhibitors.

Data from the MAGNITUDE trial support the positive benefit/risk profile of niraparib plus abiraterone acetate and prednisone as a treatment for those with BRCA-mutated metastatic castration-resistant prostate cancer.

Subgroup analyses in the phase 3 KEYNOTE-641 trial do not indicate an overall survival improvement with pembrolizumab plus enzalutamide in metastatic castration-resistant prostate cancer.

Findings from the ENZA-p study provide evidence for enhanced anti-cancer effects with 177Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer.

Findings from a meta-analysis highlight the effect of varying censorship criteria for the definition of surrogate end points in localized prostate cancer randomized clinical trials.

Germline testing may elucidate important mutations in patients with metastatic prostate cancer who may be eligible to receive treatment with PARP inhibitors, according to Neeraj Agarwal, MD.

Over half of all patients with small cell neuroendocrine prostate cancer treated with BXCL701 and pembrolizumab were alive at 1 year in a phase 2 trial.